nach oben

Erschienen in:

18.10.2021 | Review Article

Imaging of Colorectal Liver Metastasis

verfasst von: Azarakhsh Baghdadi, Sahar Mirpour, Maryam Ghadimi, Mina Motaghi, Bita Hazhirkarzar, Timothy M. Pawlik, Ihab R. Kamel

Erschienen in: Journal of Gastrointestinal Surgery | Ausgabe 1/2022

Einloggen, um Zugang zu erhalten

Abstract

Colorectal cancer (CRC) is one of the most common cancers in the world. The most important determinant of survival and prognosis is the stage and presence of metastasis. The liver is the most common location for CRC metastasis. The only curative treatment for CRC liver metastasis (CRLM) is resection; however, many patients are ineligible for surgical resection of CRLM. Locoregional treatments such as ablation and intra-arterial therapy are also available for patients with CRLM. Assessment of response after chemotherapy is challenging due to anatomical and functional changes. Antiangiogenic agents such as bevacizumab that are used in the treatment of CRLM may show atypical patterns of response on imaging. It is vital to distinguish patterns of response in addition to toxicities to various treatments. Imaging plays a critical role in evaluating the characteristics of CRLM and the approach to treatment. CT is the modality of choice in the diagnosis and management of CRLM. MRI is best used for indeterminate lesions and to assess response to intra-arterial therapy. PET-CT is often utilized to detect extrahepatic metastasis. State-of-the-art imaging is critical to characterize patterns of response to various treatments. We herein review the imaging characteristics of CRLM with an emphasis on imaging changes following the most common CRLM treatments.

Mármol I, Sánchez-de-Diego C, Dieste AP, Cerrada E, Yoldi MJR. Colorectal carcinoma: A general overview and future perspectives in colorectal cancer. International Journal of Molecular Sciences. 2017;18(1).

Hazhirkarzar B, Khoshpouri P, Shaghaghi M, Ghasabeh MA, Pawlik TM, Kamel IR. Current state of the art imaging approaches for colorectal liver metastasis. Hepatobiliary Surgery and Nutrition. 2020;9(1):35–48.PubMedPubMedCentralCrossRef

Tirumani SH, Kim KW, Nishino M, Howard SA, Krajewski KM, Jagannathan JP, et al. Update on the role of imaging in management of metastatic colorectal cancer. Radiographics. 2014;34(7):1908–28.PubMedCrossRef

Kopetz S, Chang GJ, Overman MJ, Eng C, Sargent DJ, Larson DW, et al. Improved survival in metastatic colorectal cancer is associated with adoption of hepatic resection and improved chemotherapy. Journal of Clinical Oncology. 2009;27(22):3677–83.PubMedPubMedCentralCrossRef

Viganò L, Ferrero A, lo Tesoriere R, Capussotti L. Liver surgery for colorectal metastases: Results after 10 years of follow-up. Long-term survivors, late recurrences, and prognostic role of morbidity. Annals of Surgical Oncology. 2008;15(9):2458–64.PubMedCrossRef

Fong Y, Fortner J, Sun RL, Brennan MF, Blumgart LH. Clinical Score for Predicting Recurrence After Hepatic Resection for Metastatic Colorectal Cancer. Annals of Surgery [Internet]. 1999;230(3):309. Available from: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1420876/. Accessed 1 Jun 2021.

Mainenti PP. Non-invasive diagnostic imaging of colorectal liver metastases. World Journal of Radiology. 2015;7(7):157.PubMedPubMedCentralCrossRef

Panel E, Kathryn I, Kaur H, Cash BD, Feig BW, Gage KL, et al. ACR Appropriateness Criteria â Pretreatment Staging of Colorectal Cancer. Journal of the American College of Radiology [Internet]. 2017;14(5):S234–44. Available from: https://doi.org/10.1016/j.jacr.2017.02.012

Ahn SJ, Kim JH, Park SJ, Han JK. Prediction of the therapeutic response after FOLFOX and FOLFIRI treatment for patients with liver metastasis from colorectal cancer using computerized CT texture analysis. European Journal of Radiology. 2016 Oct 1;85(10):1867–74.

10.

Jones RP, Jackson R, Dunne DFJ, Malik HZ, Fenwick SW, Poston GJ, et al. Systematic review and meta-analysis of follow-up after hepatectomy for colorectal liver metastases. British Journal of Surgery. 2012;99(4):477–86.CrossRef

11.

Wiering B, Krabbe PFM, Jager GJ, Oyen WJG, Ruers TJM. The impact of fluor-18-deoxyglucose-positron emission tomography in the management of colorectal liver metastases: A systematic review and metaanalysis. Cancer. 2005;104(12):2658–70.PubMedCrossRef

12.

Bajpai S, Sahani D v. Recent progress in imaging of colorectal cancer liver metastases. Current Colorectal Cancer Reports. 2009;5(2):99–107.CrossRef

13.

Sica GT, Ji H, Ros PR. CT and MR Imaging of Hepatic Metastases. 2000;(March):691–8.

14.

Adam R, de Gramont A, Figueras J, Kokudo N, Kunstlinger F, Loyer E, et al. Managing synchronous liver metastases from colorectal cancer: A multidisciplinary international consensus. Vol. 41, Cancer Treatment Reviews. W.B. Saunders Ltd; 2015. p. 729–41.

15.

Rojas Llimpe FL, di Fabio F, Ercolani G, Giampalma E, Cappelli A, Serra C, et al. Imaging in resectable colorectal liver metastasis patients with or without preoperative chemotherapy: Results of the PROMETEO-01 study. British Journal of Cancer. 2014 Aug 12;111(4):667–73.PubMedPubMedCentralCrossRef

16.

Xu L, Cai S, Cai G, Peng W. Imaging diagnosis of colorectal liver metastases. 2011;17(42):4654–9.

17.

Kanematsu M, Kondo H, Goshima S, Kato H, Tsuge U, Hirose Y, et al. Imaging liver metastases: Review and update. European Journal of Radiology. 2006;58(2):217–28.PubMedCrossRef

18.

Wicherts DA, de Haas RJ, van Kessel CS, Bisschops RHC, Takahara T, van Hillegersberg R, et al. Incremental value of arterial and equilibrium phase compared to hepatic venous phase CT in the preoperative staging of colorectal liver metastases: An evaluation with different reference standards. European Journal of Radiology. 2011;77(2):305–11.PubMedCrossRef

19.

Kodzwa R. ACR manual on contrast media: 2018 updates. Vol. 91, Radiologic Technology. 2019. 97–100.

20.

Nadolski GJ, Stavropoulos SW. Contrast alternatives for iodinated contrast allergy and renal dysfunction: Options and limitations. Journal of Vascular Surgery [Internet]. 2013;57(2):593–8. Available from: https://doi.org/10.1016/j.jvs.2012.10.009

21.

Caraiani C, Petresc B, Dong Y, Dietrich CF. Contraindications and adverse effects in abdominal imaging. Medical Ultrasonography. 2019;21(4):456–63.PubMedCrossRef

22.

Tsili AC, Alexiou G, Naka C, Argyropoulou MI. Imaging of colorectal cancer liver metastases using contrast-enhanced US, multidetector CT, MRI, and FDG PET/CT: a meta-analysis. Acta Radiologica. SAGE Publications Inc.; 2020.

23.

Cantisani V, Grazhdani H, Fioravanti C, Rosignuolo M, Calliada F, Messineo D, et al. Liver metastases: Contrast-enhanced ultrasound compared with computed tomography and magnetic resonance. World Journal of Gastroenterology. WJG Press; 2014. p. 9998–10007.

24.

Kaur H, Hindman NM, Al-Refaie WB, Arif-Tiwari H, Cash BD, Chernyak V, et al. ACR Appropriateness Criteria® Suspected Liver Metastases. Journal of the American College of Radiology [Internet]. 2017;14(5):S314–25. Available from: https://doi.org/10.1016/j.jacr.2017.01.037

25.

Grazioli L, Morana G, Kirchin MA, Schneider G. Accurate Differentiation of Focal Nodular Hyperplasia from Hepatic Adenoma at Gadobenate Dimeglumine–enhanced MR Imaging: Prospective Study. Radiology [Internet]. 2005 Jul;236(1):166–77. Available from: http://pubs.rsna.org/doi/10.1148/radiol.2361040338

26.

Niekel MC, Bipat S, Stoker J. Diagnostic imaging of colorectal liver metastases with CT, MR imaging, FDG PET, and/or FDG PET/CT: A meta-analysis of prospective studies including patients who have not previously undergone treatment. Radiology. 2010;257(3):674–84.PubMedCrossRef

27.

Ong KO, Leen E. Radiological staging of colorectal liver metastases. Surgical Oncology. 2007.

28.

Namasivayam S, Martin DR, Saini S. Imaging of liver metastases: MRI. Cancer Imaging. 2007;7(1):2–9.PubMedPubMedCentralCrossRef

29.

Kamel IR, Bluemke DA. MR imaging of liver tumors. Radiologic Clinics of North America. 2003;41(1):51–65.PubMedCrossRef

30.

Dillman JR, Ellis JH, Cohan RH, Strouse PJ, Jan SC. Allergic-like breakthrough reactions to gadolinium contrast agents after corticosteroid and antihistamine premedication. American Journal of Roentgenology. 2008;190(1):187–90.PubMedCrossRef

31.

Mavrogeni SI, Poulos G, Kolovou G, Theodorakis G. Magnetic resonance imaging-conditional devices: Luxury or real clinical need? Hellenic Journal of Cardiology [Internet]. 2017;58(4):256–60. Available from: https://doi.org/10.1016/j.hjc.2017.01.001

32.

Xu LH, Cai SJ, Cai GX, Peng WJ. Imaging diagnosis of colorectal liver metastases. World Journal of Gastroenterology. 2011 Nov 14;17(42):4654–9.PubMedPubMedCentralCrossRef

33.

Baghdadi A, Ghadimi M, Mirpour S, Hazhirkarzar B, Motaghi M, Pawlik TM, et al. Imaging neuroendocrine tumors: Characterizing the spectrum of radiographic findings. Surgical Oncology [Internet]. 2021 Jun;37:101529. Available from: https://linkinghub.elsevier.com/retrieve/pii/S0960740421000189. Accessed 1 Jun 2021.

34.

Shaghaghi M, AliyariG hasabeh M, Ameli S, Ghadimi M, Hazhirkarzar B, Rezvani Habibabadi R, et al. Role of tumor margin and ADC change in defining the need for additional treatments after the first TACE in patients with unresectable HCC. European Journal of Radiology. 2020 Dec 1;133.

35.

36.

Kenis C, Deckers F, de Foer B, van Mieghem F, van Laere S, Pouillon M. Diagnosis of liver metastases: Can diffusion-weighted imaging (DWI) be used as a stand alone sequence? European Journal of Radiology. 2012;81(5):1016–23.PubMedCrossRef

37.

So JS, Cheong C, Oh SY, Lee JH, Kim YB, Suh KW. Accuracy of preoperative local staging of primary colorectal cancer by using computed tomography: Reappraisal based on data collected at a highly organized cancer center. Annals of Coloproctology. 2017;33(5):192–6.PubMedPubMedCentralCrossRef

38.

Schima W, Kulinna C, Langenberger H, Ba-Ssalamah A. Liver metastases of colorectal cancer: US, CT or MR? Vol. 5 Spec No A, Cancer imaging : the official publication of the International Cancer Imaging Society. 2005.

39.

Patel S, Cheek S, Osman H, Jeyarajah DR. MRI with Gadoxetate Disodium for Colorectal Liver Metastasis: Is It the New “Imaging Modality of Choice”? Journal of Gastrointestinal Surgery. 2014;18(12):2130–5.PubMedCrossRef

40.

Yang YYL, Fleshman JW, Strasberg SM. Detection and management of extrahepatic colorectal cancer in patients with resectable liver metastases. Journal of Gastrointestinal Surgery. 2007;11(7):929–44.PubMedCrossRef

41.

Huebner RH, Park KC, Shepherd JE, Schwimmer J, Czernin J, Phelps ME, et al. A meta-analysis of the literature for whole-body FDG PET detection of recurrent colorectal cancer. Journal of Nuclear Medicine. 2000;41(7):1177–89.PubMed

42.

Ruers TJM, Langenhoff BS, Neeleman N, Jager GJ, Strijk S, Wobbes T, et al. Value of positron emission tomography with [F-18]fluorodeoxyglucose in patients with colorectal liver metastases: A prospective study. Journal of Clinical Oncology. 2002;20(2):388–95.PubMedCrossRef

43.

Rappeport ED, Loft A. Liver metastases from colorectal cancer: Imaging with superparamagnetic iron oxide (SPIO)-enhanced MR imaging, computed tomography and positron emission tomography. Abdominal Imaging. 2007;32(5):624–34.PubMedCrossRef

44.

de Geus-Oei LF, Oyen WJG. Predictive and prognostic value of FDG-PET. Cancer Imaging. 2008;8(1):70–80.PubMedPubMedCentralCrossRef

45.

van Kessel CS, Buckens CFM, van den Bosch MAAJ, van Leeuwen MS, van Hillegersberg R, Verkooijen HM. Preoperative imaging of colorectal liver metastases after neoadjuvant chemotherapy: A meta-analysis. Annals of Surgical Oncology. 2012;19(9):2805–13.PubMedPubMedCentralCrossRef

46.

Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, et al. New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1). European Journal of Cancer [Internet]. 2009;45(2):228–47. Available from: https://doi.org/10.1016/j.ejca.2008.10.026

47.

Aloysius MM, Zaitoun AM, Beckingham IJ, Neal KR, Aithal GP, Bessell EM, et al. The pathological response to neoadjuvant chemotherapy with FOLFOX-4 for colorectal liver metastases: A comparative study. Virchows Archiv. 2007;451(5):943–8.PubMedCrossRef

48.

Robinson PJA. The effects of cancer chemotherapy on liver imaging. European Radiology. 2009;19(7):1752–62.PubMedCrossRef

49.

Robinson PJA. Imaging liver metastases: Current limitations and future prospects. British Journal of Radiology. 2000;73(867):234–41.CrossRef

50.

Shinagare AB, Jagannathan JP, Krajewski KM, Ramaiya NH. Liver metastases in the era of molecular targeted therapy: New faces of treatment response. American Journal of Roentgenology. 2013;201(1):15–28.CrossRef

51.

Garcia J, Hurwitz HI, Sandler AB, Miles D, Coleman RL, Deurloo R, et al. Bevacizumab (Avastin®) in cancer treatment: A review of 15 years of clinical experience and future outlook. Cancer Treatment Reviews [Internet]. 2020;86(December 2019):102017. Available from: https://doi.org/10.1016/j.ctrv.2020.102017

52.

Rosen LS, Jacobs IA, Burkes RL. Bevacizumab in Colorectal Cancer: Current Role in Treatment and the Potential of Biosimilars. Targeted Oncology. 2017;12(5):599–610.PubMedPubMedCentralCrossRef

53.

Chung WS, Park MS, Shin SJ, Baek SE, Kim YE, Choi JY, et al. Response evaluation in patients with colorectal liver metastases: RECIST version 1.1 versus modified CT criteria. American Journal of Roentgenology. 2012;199(4):809–15.PubMedCrossRef

54.

Ward J, Guthrie JA, Sheridan MB, Boyes S, Smith JT, Wilson D, et al. Sinusoidal obstructive syndrome diagnosed with superparamagnetic iron oxide-enhanced magnetic resonance imaging in patients with chemotherapy-treated colorectal liver metastases. Journal of Clinical Oncology. 2008;26(26):4304–10.PubMedCrossRef

55.

Fowler KJ, Linehan DC, Menias CO. Colorectal liver metastases: State of the art imaging. Annals of Surgical Oncology. 2013;20(4):1185–93.PubMedCrossRef

56.

Jadvar H. The Use of Imaging in the Prediction and Assessment of Cancer Treatment Toxicity. Diagnostics. 2017;7(3):43.PubMedCentralCrossRef

57.

Martin J, Petrillo A, Smyth EC, Shaida N, Khwaja S, Cheow H, et al. Colorectal liver metastases: Current management and future perspectives. Vol. 11, World Journal of Clinical Oncology. 2020. 761–808.

58.

Chen W, Zhuang H, Cheng G, Torigian DA, Alavi A. Comparison of FDG-PET, MRI and CT for post radiofrequency ablation evaluation of hepatic tumors. Annals of Nuclear Medicine. 2013;27(1):58–64.PubMedCrossRef

59.

Kim Y sun, Rhim H, Lim HK, Choi D, Lee MW, Park MJ. Coagulation necrosis induced by radiofrequency ablation in the liver: Histopathologic and radiologic review of usual to extremely rare changes. Radiographics. 2011;31(2):377–90.

60.

Donckier V, van Laethem JL, Goldman S, van Gansbeke D, Feron P, Ickx B, et al. [F-18] Fluorodeoxyglucose Positron Emission Tomography as a Tool for Early Recognition of Incomplete Tumor Destruction after Radiofrequency Ablation for Liver Metastases. Journal of Surgical Oncology. 2003;84(4):215–23.PubMedCrossRef

61.

Sahani D, Mehta A, Blake M, Prasad S, Harris G, Saini S. Preoperative hepatic vascular evaluation with CT and MR angiography: Implications for surgery. Radiographics. 2004;24(5):1367–80.PubMedCrossRef

62.

Chinese SODM, Liver CCOCMDA, Clinical PMCOCMDA, Digital ISCOCRHA. Clinical practice guidelines for precision diagnosis and treatment of complex liver tumor guided by three-dimensional visualization technology (version 2019). Nan fang yi ke da xue xue bao = Journal of Southern Medical University. 2020;40(3):297–307.

63.

Mattar RE, Al-Alem F, Simoneau E, Hassanain M. Preoperative selection of patients with colorectal cancer liver metastasis for hepatic resection. World Journal of Gastroenterology. 2016;22(2):567–81.PubMedPubMedCentralCrossRef

64.

Ghadimi M, Pandey P, Rezvani Habibabadi R, Motaghi M, Shaghaghi M, Khoshpouri P, et al. Role of volumetric multiparametric MRI in distinguishing between intraductal papillary mucinous neoplasms and serous cystadenoma. Abdominal Radiology [Internet]. 2021 Apr 9;46(4):1629–39. Available from: https://link.springer.com/10.1007/s00261-020-02792-0CrossRef

65.

66.

Hazhirkarzar B, Tang H, Ghadimi M, Baghdadi A, Motaghi M, Wu Q, et al. Predicting early necrosis of colorectal liver metastases using volumetric enhancement on baseline MRI and oil deposition on post-cTACE unenhanced CT. Abdominal Radiology [Internet]. 2021 Jun 4; Available from: https://link.springer.com/10.1007/s00261-021-03133-5

67.

Küstner T, Hepp T, Fischer M, Schwartz M, Fritsche A, Häring H-U, et al. Fully Automated and Standardized Segmentation of Adipose Tissue Compartments via Deep Learning in 3D Whole-Body MRI of Epidemiologic Cohort Studies. Radiology: Artificial Intelligence [Internet]. 2020 Nov 1;2(6):e200010. Available from: http://pubs.rsna.org/doi/10.1148/ryai.2020200010

68.

Fu Y, Lei Y, Wang T, Tian S, Patel P, Jani AB, et al. Pelvic multi-organ segmentation on cone-beam CT for prostate adaptive radiotherapy. Medical Physics [Internet]. 2020 Aug 11;47(8):3415–22. Available from: https://onlinelibrary.wiley.com/doi/10.1002/mp.14196PubMedPubMedCentralCrossRef

69.

Fernandez H, Nadalin S, Testa G. Optimizing future remnant liver prior to major hepatectomies: increasing volume while decreasing morbidity and mortality. Hepatobiliary Surgery and Nutrition. 2020;9(2):215–8.PubMedPubMedCentralCrossRef

70.

Alberts SR, Poston GJ. Treatment advances in liver-limited metastatic colorectal cancer. Clinical Colorectal Cancer [Internet]. 2011;10(4):258–65. Available from: https://doi.org/10.1016/j.clcc.2011.06.008

71.

Ganeshan DM, Szklaruk J. Portal vein embolization: Cross-sectional imaging of normal features and complications. American Journal of Roentgenology. 2012;199(6):1275–82.PubMedCrossRef

72.

Yeom YK, Shin JH. Complications of portal vein embolization: Evaluation on cross-sectional imaging. Korean Journal of Radiology. 2015;16(5):1079–85.PubMedPubMedCentralCrossRef

73.

Araujo RLC, Milani JM, Armentano DP, Moreira RB, Pinto GSF, de Castro LA, et al. Disappearing colorectal liver metastases: Strategies for the management of patients achieving a radiographic complete response after systemic chemotherapy. Journal of Surgical Oncology. 2020;121(5):848–56.PubMed

74.

Owen JW, Fowler KJ, Doyle MB, Saad NE, Linehan DC, Chapman WC. Colorectal liver metastases: disappearing lesions in the era of Eovist hepatobiliary magnetic resonance imaging. Hpb [Internet]. 2016;18(3):296–303. Available from: https://doi.org/10.1016/j.hpb.2015.10.009

75.

Kuhlmann K, van Hilst J, Fisher S, Poston G. Management of disappearing colorectal liver metastases. European Journal of Surgical Oncology [Internet]. 2016;42(12):1798–805. Available from: https://doi.org/10.1016/j.ejso.2016.05.005

76.

Bischof DA, Clary BM, Maithel SK, Pawlik TM. Surgical management of disappearing colorectal liver metastases. British Journal of Surgery. 2013;100(11):1414–20.CrossRef

77.

Melstrom LG, Warner SG, Wong P, Sun V, Raoof M, Singh G, et al. Management of disappearing colorectal liver metastases: an international survey. Hpb [Internet]. 2021;23(4):506–11. Available from: https://doi.org/10.1016/j.hpb.2020.10.005

78.

Oba A, Mise Y, Ito H, Hiratsuka M, Inoue Y, Ishizawa T, et al. Clinical implications of disappearing colorectal liver metastases have changed in the era of hepatocyte-specific MRI and contrast-enhanced intraoperative ultrasonography. Hpb [Internet]. 2018;20(8):708–14. Available from: https://doi.org/10.1016/j.hpb.2018.02.377

Titel: Imaging of Colorectal Liver Metastasis
verfasst von: Azarakhsh Baghdadi
Sahar Mirpour
Maryam Ghadimi
Mina Motaghi
Bita Hazhirkarzar
Timothy M. Pawlik
Ihab R. Kamel
Publikationsdatum: 18.10.2021
Verlag: Springer US
Erschienen in: Journal of Gastrointestinal Surgery / Ausgabe 1/2022
Print ISSN: 1091-255X
Elektronische ISSN: 1873-4626
DOI: https://doi.org/10.1007/s11605-021-05164-1

Neu im Fachgebiet Chirurgie

23.04.2024 | Ablationstherapie | Nachrichten

Wie erfolgreich ist eine Re-Ablation nach Rezidiv?

23.04.2024 | Appendizitis | Nachrichten

Hinter dieser Appendizitis steckte ein Erreger

23.04.2024 | Operationsvorbereitung | Nachrichten

Mehr Schaden als Nutzen durch präoperatives Aussetzen von GLP-1-Agonisten?

19.04.2024 | EAU 2024 | Kongressbericht | Nachrichten

Ureterstriktur: Innovative OP-Technik bewährt sich

weitere anzeigen

Update Chirurgie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Aktuelle BDC Leitlinien-Webinare

S3-Leitlinie „Diagnostik und Therapie des Karpaltunnelsyndroms“

Karpaltunnelsyndrom BDC Leitlinien Webinare

CME: 2 Punkte

Das Karpaltunnelsyndrom ist die häufigste Kompressionsneuropathie peripherer Nerven. Obwohl die Anamnese mit dem nächtlichen Einschlafen der Hand (Brachialgia parästhetica nocturna) sehr typisch ist, ist eine klinisch-neurologische Untersuchung und Elektroneurografie in manchen Fällen auch eine Neurosonografie erforderlich. Im Anfangsstadium sind konservative Maßnahmen (Handgelenksschiene, Ergotherapie) empfehlenswert. Bei nicht Ansprechen der konservativen Therapie oder Auftreten von neurologischen Ausfällen ist eine Dekompression des N. medianus am Karpaltunnel indiziert.

Prof. Dr. med. Gregor Antoniadis

S2e-Leitlinie „Distale Radiusfraktur“

Radiusfraktur BDC Leitlinien Webinare

CME: 2 Punkte

Das Webinar beschäftigt sich mit Fragen und Antworten zu Diagnostik und Klassifikation sowie Möglichkeiten des Ausschlusses von Zusatzverletzungen. Die Referenten erläutern, welche Frakturen konservativ behandelt werden können und wie. Das Webinar beantwortet die Frage nach aktuellen operativen Therapiekonzepten: Welcher Zugang, welches Osteosynthesematerial? Auf was muss bei der Nachbehandlung der distalen Radiusfraktur geachtet werden?

PD Dr. med. Oliver Pieske

Dr. med. Benjamin Meyknecht

S1-Leitlinie „Empfehlungen zur Therapie der akuten Appendizitis bei Erwachsenen“

Appendizitis BDC Leitlinien Webinare

CME: 2 Punkte

Inhalte des Webinars zur S1-Leitlinie „Empfehlungen zur Therapie der akuten Appendizitis bei Erwachsenen“ sind die Darstellung des Projektes und des Erstellungswegs zur S1-Leitlinie, die Erläuterung der klinischen Relevanz der Klassifikation EAES 2015, die wissenschaftliche Begründung der wichtigsten Empfehlungen und die Darstellung stadiengerechter Therapieoptionen.

Dr. med. Mihailo Andric

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 1/2022

The Effect of Facility Volume on Survival Following Proctectomy for Rectal Cancer

Early Versus Late Recurrence in Rectal Cancer: Does Timing Matter?

Impact of the Affordable Care Act Medicaid Expansion on Reimbursement in Emergency General Surgery

Extent of Lymph Node Dissection for Accurate Staging in Intrahepatic Cholangiocarcinoma

Outcomes of Gastric Conduit in Corrosive Esophageal Stricture: a Systematic Review and Meta-analysis

Language Proficiency and Survival in Pancreatic Cancer: a Propensity Score–Matched Analysis

Neu im Fachgebiet Chirurgie

Wie erfolgreich ist eine Re-Ablation nach Rezidiv?

Hinter dieser Appendizitis steckte ein Erreger

Mehr Schaden als Nutzen durch präoperatives Aussetzen von GLP-1-Agonisten?

Ureterstriktur: Innovative OP-Technik bewährt sich

Update Chirurgie

Aktuelle BDC Leitlinien-Webinare

S3-Leitlinie „Diagnostik und Therapie des Karpaltunnelsyndroms“

S2e-Leitlinie „Distale Radiusfraktur“

S1-Leitlinie „Empfehlungen zur Therapie der akuten Appendizitis bei Erwachsenen“